3.3 Geriatric Pharmacotherapy & Drug-Nutrient Interactions
Key Takeaways
Review prescriptions, over-the-counter medicines, and supplements together when assessing polypharmacy.
Diuretics can alter potassium, magnesium, and fluid balance; restrictions and replacement need clinical monitoring.
Calcium citrate is less acid-dependent; carbonate absorption improves when taken with food.
Levodopa competes with amino acids in intestinal and blood-brain transport; adjust timing without reducing overall protein adequacy.
Beers Criteria advises avoiding megestrol in older adults because limited benefit is outweighed by serious risks.
3.3 Geriatric Pharmacotherapy & Drug-Nutrient Interactions
Pharmacotherapy in gerontology is complicated by age-related physiological changes that alter pharmacokinetics and pharmacodynamics. The simultaneous presence of multiple chronic diseases drives polypharmacy, classically defined as the concurrent use of five or more routine medications (with ten or more termed hyperpolypharmacy). In the United States, nearly 40% of older adults aged 65 and older take five or more prescription medications. Polypharmacy multiplies the risk of adverse drug reactions, prescribing cascades, drug-drug interactions, and clinically significant drug-nutrient interactions. For the Board Certified Specialist in Gerontological Nutrition (CSG), recognizing these interactions is vital to prevent iatrogenic malnutrition, dehydration, cognitive decline, and metabolic collapse.
Age-Related Pharmacokinetics & The AGS Beers Criteria
Aging alters every phase of clinical drug handling:
- Absorption: Reduced gastric acid production (hypochlorhydria) and delayed gastric emptying alter the dissolution and bioavailability of enteric-coated and pH-sensitive drugs.
- Distribution: Sarcopenia and reduced total body water contract the distribution volume for hydrophilic compounds (e.g., digoxin, lithium, cimetidine), resulting in elevated peak plasma concentrations. In contrast, increased relative body fat expands the distribution volume for lipophilic drugs (e.g., diazepam, amiodarone), markedly prolonging their elimination half-life. Hypoalbuminemia from illness or other causes can alter the unbound fraction of protein-bound drugs; it is not an inevitable nutritional consequence of normal aging.
- Metabolism: Hepatic blood flow and some metabolic pathways may decline with aging or illness, but effects vary by drug and individual; there is no universal percentage reduction in CYP clearance.
- Excretion: Progressive decline in renal blood flow and glomerular filtration rate diminishes the clearance of renally eliminated drugs and active metabolites, leading to toxic accumulation.
The AGS Beers Criteria for Potentially Inappropriate Medication Use
The American Geriatrics Society (AGS) maintains the Beers Criteria to guide clinicians away from medications that present disproportionate risks in older adults:
- Anticholinergic Medications: First-generation antihistamines (diphenhydramine, hydroxyzine), tricyclic antidepressants (amitriptyline), and bladder antimuscarinics (oxybutynin, tolterodine) impose severe anticholinergic burden. Nutritional consequences include severe xerostomia (dry mouth impairing mastication, blunting taste, destabilizing dentures, and precipitating dysphagia), chronic constipation/fecal impaction, and cognitive delirium.
- Sedatives & Hypnotics: Benzodiazepines and non-benzodiazepine receptor agonists ("Z-drugs" such as zolpidem) cause residual morning sedation, leading to missed breakfast, uncoordinated chewing, and severe aspiration risk during meals.
- Sliding-Scale Regular Insulin: Use of short-acting insulin regimens based solely on current blood glucose without basal coverage causes sharp glycemic swings and severe hypoglycemia without improving glycemic control.
High-Yield Drug-Nutrient Interactions in Gerontological Nutrition
The following table provides a comprehensive clinical reference for high-yield drug-nutrient interactions routinely encountered on the CSG exam:
| Medication Class & Examples | Primary Mechanism of Action | Nutrient Impact & Biochemical Consequences | Clinical Nutrition Intervention |
|---|---|---|---|
| Loop Diuretics (e.g., Furosemide, Bumetanide) | Inhibits symporter in thick ascending limb of Henle | Excessive urinary wasting of potassium, magnesium, calcium, and thiamine (); prerenal azotemia | Monitor serum and ; encourage potassium-rich foods or supplements; monitor thiamine status in chronic HF |
| Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene) | Spironolactone antagonizes aldosterone; triamterene blocks epithelial sodium channels in the distal nephron | Potassium retention leading to severe hyperkalemia, especially with ACE inhibitors, ARBs, or CKD | Avoid potassium supplements; warn against salt substitutes containing potassium chloride () |
| Proton Pump Inhibitors (PPIs) (e.g., Omeprazole, Pantoprazole) | Irreversible inhibition of pump in gastric parietal cells | Profound hypochlorhydria; impaired cleavage of vitamin from food protein; reduced absorption of calcium carbonate, iron, and magnesium | Consider calcium citrate; carbonate is better absorbed with meals; monitor serum , ferritin, and magnesium |
| Levodopa / Carbidopa (Sinemet) | Dopamine precursor that crosses blood-brain barrier via LAT1 transporter | Competes with dietary large neutral amino acids (LNAAs) for intestinal absorption and blood-brain barrier transport | Administer 30–60 minutes before or 1–2 hours after meals; consider protein-redistribution diet |
| Warfarin (Coumadin) | Inhibits vitamin K epoxide reductase, blocking activation of clotting factors II, VII, IX, X | Fluctuations in dietary vitamin K (phylloquinone) alter INR; herbal interactions (Ginkgo, garlic, ginger, ginseng, St. John's wort) | Maintain consistent daily vitamin K intake; do NOT eliminate greens; avoid bleeding-risk botanicals |
| Digoxin | Cardiac sodium/potassium-ATPase inhibition | Low potassium or magnesium increases toxicity risk | Review renal function, drug level, electrolytes, licorice use, and interactions with the treating team. |
| Metformin (Glucophage) | Inhibits hepatic gluconeogenesis and improves peripheral insulin sensitivity | Calcium-dependent competitive inhibition of ileal vitamin -intrinsic factor absorption; lactic acidosis risk in renal decline | Consider periodic B12 assessment, especially with anemia or neuropathy; discontinue if eGFR ; do not initiate at eGFR 30–45; if eGFR falls below 45 during treatment, the prescriber reassesses benefit/risk and dosing |
| Corticosteroids (e.g., prednisone) | Glucocorticoid effects | Hyperglycemia, fluid/electrolyte changes, bone loss, and muscle catabolism | Monitor intake, glucose, and bone risk; individualize calcium/vitamin D and other treatment. |
Critical Mechanistic Nuances for Clinical Practice
1. Loop Diuretics & Thiamine Wasting
While hypokalemia and hypomagnesemia are standard clinical concerns with loop diuretics, chronic furosemide therapy accelerates urinary thiamine excretion through forced diuresis. In heart failure patients, occult thiamine deficiency depresses myocardial energetic efficiency, worsening ventricular failure and mimicking refractory cardiomyopathy (cardiac wet beriberi). Assess thiamine risk from intake, losses, alcohol use, and illness. A particular furosemide dose or ejection fraction does not diagnose deficiency or justify routine supplementation without review.
2. PPIs and Calcium Form
Calcium carbonate absorption is more acid-dependent, particularly when fasting. Taking carbonate with meals can improve absorption in low-acid conditions; it does not simply pass through universally unabsorbed. Calcium citrate is less dependent on gastric acidity and may be a practical choice. Review elemental calcium from food plus supplements, tolerability, kidney function, and the indication before changing products.
3. Levodopa & Large Neutral Amino Acid Competition
Levodopa is a large neutral amino acid (LNAA). It competes with dietary amino acids at intestinal transport systems and at LAT1 across the blood-brain barrier; the intestinal mechanism is not exclusively LAT1. When an older adult consumes protein-rich meals (meat, eggs, dairy, protein supplements), dietary LNAAs (leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan) saturate the LAT1 carrier. Levodopa is outcompeted and fails to enter the central nervous system, triggering abrupt, disabling "off" periods and Parkinsonian freezing.
- Clinical Nutrition Protocols: First-line management is dosing carbidopa/levodopa 30 to 60 minutes before meals or 1 to 2 hours postprandially on an empty stomach. For residents with severe daytime motor fluctuations, an evidence-based Protein-Redistribution Diet shifts the majority of dietary protein to the evening meal (dinner), maintaining low protein intake () during breakfast and lunch to ensure daytime motor mobility.
4. Warfarin & Dietary Consistency
Warfarin functions as a competitive inhibitor of vitamin K epoxide reductase complex 1 (VKORC1). The clinical goal is consistency of dietary phylloquinone intake, not total elimination. Restricting green vegetables is nutritionally harmful, depriving the resident of carotenoids, potassium, and dietary fiber. Maintain a reasonably consistent pattern of vitamin K intake and discuss major changes with the anticoagulation team. Audit every botanical and supplement: interaction evidence and direction vary by product. American ginseng has reduced warfarin effect in a controlled study; Asian-ginseng results are mixed. Garlic, ginkgo, high-dose vitamin E, and other products may affect bleeding risk. St. John’s wort can reduce anticoagulant effect through enzyme induction. The “4 G” mnemonic does not mean every product increases INR or has an identical mechanism.
Pharmacological Appetite Stimulants in Geriatric Practice
When non-pharmacological mealtime adaptations, flavor enhancement, and oral nutrition supplements fail to arrest severe unintended weight loss, clinicians often consider appetite stimulants. However, the geriatric risk-to-benefit profile for these agents is heavily skewed toward adverse outcomes.
1. Mirtazapine (Remeron)
Mirtazapine is an atypical antidepressant featuring central presynaptic -adrenergic antagonism, and receptor antagonism, and potent histamine antagonism.
- Clinical Role: Mirtazapine can increase appetite and weight during depression treatment, but evidence does not justify routine use solely as an appetite stimulant in a person without depression. Dosing and sedation risk require prescriber review.
2. Megestrol Acetate (Megace): Critical Beers Criteria Warning
Megestrol acetate is a synthetic progestin originally developed for breast and endometrial cancers. It is widely prescribed off-label for geriatric cachexia, but the AGS Beers Criteria strongly advises against its use:
- Ineffective Tissue Accretion: Megestrol-induced weight gain consists almost entirely of adipose tissue and fluid retention, with no increase in lean skeletal muscle mass or functional performance.
- Severe Adverse Events: Carries clinical warnings and precautions concerning venous thromboembolism (deep vein thrombosis and pulmonary embolism) and peripheral edema. Furthermore, due to its intrinsic glucocorticoid activity, megestrol suppresses the hypothalamic-pituitary-adrenal (HPA) axis, causing secondary adrenal insufficiency and steroid-induced hyperglycemia. Randomized clinical trials demonstrate increased all-cause mortality in older adults treated with megestrol acetate.
3. Dronabinol (Marinol)
Dronabinol is an orally active synthetic delta-9-tetrahydrocannabinol (THC) that stimulates central CB1 cannabinoid receptors.
- While approved for AIDS-related cachexia, its use in older adults is strictly limited by profound central nervous system neurotoxicity. Older adults experience severe somnolence, dizziness, orthostatic hypotension, euphoria/dysphoria, confusion, hallucinations, and ataxia. These CNS effects dramatically increase fall and fracture rates, making dronabinol a last-resort agent rarely appropriate for frail elders.
Primary source check
Megestrol prescribing information, checked October 13, 2026.
NIH calcium fact sheet, checked October 13, 2026.
NCCIH herb–drug interaction review, checked October 13, 2026.
A 76-year-old resident with Parkinson's disease experiences unpredictable motor fluctuations, including debilitating 'off' periods where his limbs become rigid and bradykinetic 45 minutes after lunch. His medication regimen includes carbidopa/levodopa 25/100 mg four times daily. A review of his meal logs indicates he consumes a high-protein nutritional supplement and roast beef during his midday meal. What is the primary pharmacokinetic mechanism and corresponding dietary strategy?
Levodopa binds dietary carbohydrates; high-carbohydrate meals should be shifted entirely to bedtime
Dietary fat delays levodopa breakdown in the liver; fat intake should be restricted to less than 10% of total daily calories
Amino-acid competition; review dose timing and protein distribution
Levodopa causes irreversible vitamin K malabsorption; dietary phylloquinone must be strictly avoided at lunchtime
An older adult on long-term omeprazole needs calcium supplementation and cannot reliably take tablets with meals. Which option reduces dependence on gastric acidity?
Stop all calcium because omeprazole inevitably causes hypercalcemia
Reduce calcium carbonate without assessing intake
Use IV vitamin C instead of calcium
Consider calcium citrate and assess the required elemental calcium amount
The interdisciplinary care team at a long-term care facility is discussing pharmacotherapy for an 84-year-old resident with severe anorexia and weight loss. An attending physician suggests ordering megestrol acetate (Megace) 400 mg daily. According to the AGS Beers Criteria and geriatric nutrition evidence, what guidance should the RDN provide?
Endorse megestrol acetate as the first-line gold standard for rebuilding skeletal muscle mass in frail elderly
Recommend megestrol acetate only if combined with high-dose vitamin K to prevent arterial hemorrhage
Advise against megestrol because risks outweigh limited benefit
Approve megestrol acetate provided the dose is doubled to 800 mg daily to overcome age-related receptor resistance
Sections you finish are checked off in the contents.